What EUDAMED database is?

EUDAMED is the IT system developed by the European Commission to implement Regulation (EU) 2017/745 on medical devices and Regulation 2017/746 on in vitro diagnosis medical devices. The new Regulations contain important improvements including a much larger EUDAMED database than the one that currently exists under the Medical Devices Directives (Eudamed2).

EUDAMED is the unified European medical products database. EUDAMED aims to improve transparency and coordination of information on medical devices available on the EU market.

How does it work?

EUDAMED is structured around 6 interconnected modules and a public website:

• Actors registration
• UDI/Devices registration
• Notified Bodies and Certificates
• Clinical Investigations and performance studies
• Vigilance and post-market surveillance
• Market Surveillance

One can search for medical products by manufacturer, by package number, by authorized representative, by importer and by barcode on the UDI packaging and by certificates. Every medical product listed there is sold throughout the Europe.

More

The COVID-19 pandemic significantly accelerated the adoption of decentralized clinical trials. As health system resources were expended on COVID-19-related care and travel became limited by physical distance, patient access to research facilities decreased by 80 percent.[1] In the face of such disruptions, sponsors quickly mobilized to maintain continuity of care and data integrity – for example, by adopting remote patient consent and monitoring. Although some elements of decentralization of clinical trials existed before the COVID-19 pandemic, they were not widely used in trials. And as the global pandemic continues, a consensus is emerging that many interventions will become permanent. Tools such as electronic consent, telehealth care, remote patient monitoring, and electronic clinical outcome assessments (eCOAs) make it possible to maintain contact with study participants without in-person visits.

Defining decentralized clinical trials and trying to understand them

More

Polish companies are willing to start selling cosmetics in China, however still some formal requirements stand in the way. China has recently changed its cosmetics industry regulations. Until May 1 2021, China required importers to test cosmetics on animals. It was an insurmountable barrier for European producers, because the European Union has been banned from testing cosmetics on animals for many years. Now the Chinese are demanding a certificate of Good Manufacturing Practice. It is to certify that the preparation was developed under the conditions and standards imposed by an international standard. Such certificate should be issued by the supervisory authority. The Polish certificate has not yet been created, although its content was proposed by the Polish Union of the Cosmetics Industry during the summer holidays in 2021. The Union brings together over 220 companies, including manufacturers, distributors, laboratories, consulting companies and teaching centers.

Without a proper certificate and without an efficient procedure for issuing it, the Polish cosmetics industry loses its competitiveness against other Western countries on the world’s largest market.

Experts in Poland emphasize at the same time that the certificate is not everything. It is still necessary to develop an instruction for its issuing, which will go to the poviat (local level) health care centers.

More

The Polish medical and pharmaceutical industry has a long tradition. In recent years, its structure and dynamics have changed significantly. The domestic pharmaceutical industry is one of the strategic industries of the Polish economy. It plays a key role in the whole healthcare system, providing Polish patients with examined, effective, high-quality and affordable medicines. Most Polish pharmaceutical companies have been privatized and numerous companies have been taken over by large foreign pharmaceutical corporations. In addition, new successful companies are emerging, which thanks to their innovation and implementation of new technologies, are entering foreign markets and becoming competitors of foreign companies. They also contribute to a significant increase in the competitiveness of the Polish economy.

Development in figures

More

The team of KIELTYKA GLADKOWSKI dedicated to clients operating in life science sector actively advises on all aspects of in vitro diagnostics, including regulatory, corporate and investments matters. For the purposes of such clients this text analyses the bullet points of REGULATION (EU) 2017/746 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU. Regulation 2017/746/EU (IVDR) replaces the existing Directive 98/79 / EC on in vitro diagnostic medical devices (IVDD), which was adopted in 1998.

With the publication of the IVDR, the five-year transition period from the In Vitro Diagnostic Medical Devices Directive (98/79/EC) (IVDD) to the new regulation has started. The IVDR regulation will apply from the date of application, i.e. from May 26, 2022, with some provisions, including Notified Bodies and the Medical Device Coordination Group will enter into force sooner. Until the date of application of the IVDR, the laws and regulations adopted by the Member States under the IVDD will continue to apply. Under Art. 22 of the 1998 IVDD directive, the member states were obliged to prepare and introduce the national laws, regulations and administrative provisions necessary to comply with this directive by December 7, 1999 (IVDD) at the latest. The provisions of the directive were to apply with effect from 7 June 2000. As the provisions of the directive could be interpreted differently in different countries, it was possible for national provisions to differ. In the case of EU regulations, the provisions contained therein do not have to be transposed and adapted to national law. In May 2017, the European Parliament and the Council of the European Union published two new regulations on medical devices (2017/745/EU) (MDR) and in vitro diagnostic medical devices (2017/746/EU) (IVDR). Regulation 2017/746/EU (IVDR) replaces the existing Directive 98/79/EC on in vitro diagnostic medical devices (IVDD), which was adopted in 1998.

More